Tiziana Life Sciences Ltd TLSA
Set alert
At close · Oct 30
After hours · Oct 30, 4:07 PM ET
- YTD
- -46.31%
- 1 year
- -56.52%
- Open
- 0.897
- Prev close
- 0.9047
- Mkt cap
- 101.81M
- Vol
- 1.29M
- Avg vol
- 773.63K
- EPS
- -0.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.79
- High
- 0.9162
- Forward P/E
- -13.63
- Beta
- 0.18
- Short ratio
- 0.57
- Inst. own
- 1.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 0.9492
- 200-d avg
- 0.86445
- 1y target
- 0.00
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 19, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
Key statistics
- Market cap
- 70.76M
- Enterprise value
- 78.46M
- Trailing P/E
- 0.00
- Forward P/E
- -13.63
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 37.86
- EPS (TTM)
- -0.13
- Beta
- 0.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -199.50K
- Total cash
- 1.13M
- Total debt
- 179.00K
- Return on equity
- -181.23%
- Shares outstanding
- 103.82M
- Short % of float
- 0.32%
- 50-day average
- 0.9492
- 200-day average
- 0.86445
Analyst view
Consensus: none
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2022 | ThinkEquity | init | — | Buy |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- tizianalifesciences.com
News
- Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
- Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab
- Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027
- Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
- Tiziana doses first three patients in ALS trial of nasal antibody foralumab
- Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial
- Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
- Tiziana Completes Phase 2a MS Trial, Topline Data Due In October
Your note
Sign in to keep a note on TLSA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sanctuary Advisors, LLC | 0.86% | 907,613 | 618.54K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.21% | 218,681 | 149.03K | Sep 29, 2024 |
| HSBC Holdings PLC | 0.11% | 115,365 | 78.62K | Sep 29, 2024 |
| Morgan Stanley | 0.10% | 109,747 | 74.79K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.10% | 104,291 | 71.07K | Sep 29, 2024 |
| Kovitz Investment Group Partners, Llc | 0.08% | 79,365 | 54.09K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index ETF | 0.15% | 162,797 | 110.95K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 55,884 | 38.08K | Oct 30, 2024 |